Skip to main content
  • TVM Capital GmbH promotes Dr. Hubert Birner to Managing Partner and Stefan Fischer to Chief Financial Officer

    July 8, 2013

Munich, 8 July 2013 – TVM Capital GmbH today announces two promotions: Dr. Hubert Birner, who has served with the leading independent life science and healthcare venture capital and private equity group as General Partner since the year 2000, is promoted to Managing Partner. He joins Chairman & Managing Partner, Dr. Helmut Schühsler, at the helm of the life sciences investment activities with a focus on the firm’s life science venture capital investment strategy in North America and Europe. Over his 13 year tenure with TVM Capital, he has been responsible for numerous investments in Europe as well as the United States and currently serves as Chairman of the Board of Argos Therapeutics Inc. (Durham, North Carolina) and Spepharm Holdings BV (Amsterdam, The Netherlands). He is also a member of the Board of Directors of Evotec AG (Hamburg, Germany) and Proteon Therapeutics, Inc (Kansas City, Missouri). He was also the Chairman and Vice Chairman of Direvo Biotech AG (Cologne, Germany) and Jerini AG (Berlin, Germany) which were acquired by Bayer HealthCare AG and Shire Ltd., respectively. These acquisitions were the largest M&A transactions in the history of German biotechnology. In 2010-2012 Dr. Birner led TVM Capital’s fundraising for the 7th generation life sciences venture capital fund which resulted in the formation of the new fund, TVM Life Sciences Ventures VII, in Canada and the opening of the new office in Montreal where Dr. Birner now resides. Dr. Birner has served as a Managing Partner of TVM Life Science Management in Montreal, the new advisory company to TVM LSV VII, together with Managing Partner Dr. Luc Marengere since early 2012.

Stefan Fischer joined TVM Capital in the same year as Dr. Birner and has served as General Partner Corporate Finance in Munich. He has been responsible for the corporate finance side of the investment activities of the life science team for many years and was actively involved in numerous IPOs and trade sales of TVM Capital portfolio companies. Stefan Fischer made major contributions to the fundraising of TVM Life Sciences Ventures VII and is now promoted to Chief Financial Officer of the firm. Mr. Fischer is the Chairman of the Supervisory Board of pritidenta GmbH (Leinfelden-Echterdingen, Germany), the Vice-Chairman of the Supervisory Board of Direvo IBT GmbH (Cologne, Germany) and serves as a board observer to Biovertis AG (Vienna, Austria). Mr. Fischer holds overall responsibility for the finance operations of our Munich and Montreal offices as well as for our life science venture capital funds..

“We are very pleased to announce the promotions of our two long-term partners who have over many years made major contributions to the development of the life sciences activities of TVM Capital, including the successful fundraising for our latest fund TVM LSV VII.” comments Dr. Helmut M. Schühsler, Chairman and Managing Partner of TVM Capital. “Dr. Birner and Stefan Fischer have been the driving forces for the establishment of our new office in Montreal and the first closing of the 7th generation life sciences fund. I am convinced that this new fund with its novel investment strategy and the partnership with industrial partner, Eli Lilly & Company will thrive under the leadership of Dr. Birner. Going forward we will also work together intensively to secure the best possible exits from the existing portfolio from the older fund generations.“

About TVM Capital Group

TVM Capital Group is an affiliation of globally acting venture capital and private equity firms with an operating track record of close to 30 years. Our investment teams have financed more than 250 emerging companies in across several industries since 1984. The life sciences and healthcare activities of the firm boast more than 120 investments and almost 90 exits in the last 25 years, including more than 40 initial public offerings on all major U.S. and European stock exchanges. During the last 15 years the firm has become increasingly specialized in the most attractive and high-growth verticals in the broader healthcare markets, with focus areas in financing innovative products and technologies in the European and U.S. biopharmaceutical and medical device markets, as well as healthcare services in the Middle East and India.

TVM Capital Group funds operate globally with dedicated Life Science venture capital funds advised by group members TVM Life Science Management in Montreal and TVM Capital in Munich, and its healthcare private equity fund managed by TVM Capital MENA out of Dubai.